Wedbush Securities Inc. boosted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 13.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,210 shares of the biotechnology company’s stock after acquiring an additional 500 shares during the period. Wedbush Securities Inc.’s holdings in United Therapeutics were worth $476,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of UTHR. Acadian Asset Management LLC bought a new position in United Therapeutics during the 2nd quarter worth $129,555,000. First Trust Advisors LP increased its stake in United Therapeutics by 36.3% during the 2nd quarter. First Trust Advisors LP now owns 684,956 shares of the biotechnology company’s stock worth $77,503,000 after acquiring an additional 182,409 shares during the period. LSV Asset Management increased its stake in United Therapeutics by 53.3% during the 1st quarter. LSV Asset Management now owns 420,340 shares of the biotechnology company’s stock worth $47,229,000 after acquiring an additional 146,194 shares during the period. BlackRock Inc. increased its stake in shares of United Therapeutics by 3.0% in the 1st quarter. BlackRock Inc. now owns 4,912,985 shares of the biotechnology company’s stock valued at $552,023,000 after purchasing an additional 141,416 shares during the last quarter. Finally, Mackay Shields LLC bought a new position in shares of United Therapeutics in the 1st quarter valued at $14,199,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Shares of United Therapeutics opened at $126.58 on Friday, according to MarketBeat Ratings. United Therapeutics Co. has a 52-week low of $100.57 and a 52-week high of $152.55. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.35 and a current ratio of 4.64. The firm has a market capitalization of $5.53 billion, a PE ratio of 7.10, a price-to-earnings-growth ratio of 29.40 and a beta of 1.28.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported $3.98 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.57 by $1.41. United Therapeutics had a return on equity of 34.42% and a net margin of 40.87%. The company had revenue of $444.50 million for the quarter, compared to analyst estimates of $368.63 million. During the same quarter last year, the company posted $4.37 EPS. The company’s revenue for the quarter was up .0% compared to the same quarter last year. equities research analysts expect that United Therapeutics Co. will post 14.4 earnings per share for the current year.

In related news, Director Judy D. Olian sold 600 shares of the firm’s stock in a transaction on Tuesday, June 12th. The stock was sold at an average price of $112.38, for a total transaction of $67,428.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Raymond Dwek sold 3,240 shares of the firm’s stock in a transaction on Friday, June 29th. The shares were sold at an average price of $113.07, for a total value of $366,346.80. The disclosure for this sale can be found here. Company insiders own 8.20% of the company’s stock.

UTHR has been the topic of several recent analyst reports. BidaskClub upgraded United Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, July 11th. Credit Suisse Group lifted their price target on United Therapeutics from $104.00 to $107.00 and gave the company a “neutral” rating in a research note on Tuesday, July 10th. Barclays decreased their price target on United Therapeutics from $105.00 to $95.00 and set an “underweight” rating on the stock in a research note on Thursday, May 3rd. Zacks Investment Research upgraded United Therapeutics from a “hold” rating to a “buy” rating and set a $127.00 price target on the stock in a research note on Saturday, July 7th. Finally, Cowen reiterated a “hold” rating and issued a $110.00 price target on shares of United Therapeutics in a research note on Thursday, August 2nd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. United Therapeutics has an average rating of “Hold” and a consensus price target of $138.86.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Story: Investing in Dividend Stocks

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.